Table 2.

EGFR mutational status and MET gene amplification in each primary or metastatic lesion

PatientPrimaryIMLNsLiverAd-GOmentPleuraKidneyChestRet-PSkinThyroidBowelHeartBone
1NADEL/TDEL/TDEL/mDEL/T/MDEL/TDEL/M
2DEL/T/mDEL/MDEL/T/mDEL/T/mDEL/T/mDEL/T
3DEL/MDEL/M*DEL/MDEL/MDEL/MDEL/MDEL/MDEL/MDEL/M
4NEDEL/TDEL/T
5L858R/TL858R/TL858R/T
6DELDEL/T*DEL/T

Abbreviations: IM, intrapulmonary metastasis; LN, mediastinal or hilar lymph nodes; Ad-G, adrenal gland; Oment, omentum; Chest, chest wall; Ret-P, retroperitoneum; Bowel, small intestine; NA, not available; DEL, exon 19 deletion mutation; T, T790M mutation; m, MET gene copy number gain (2- to 4-fold compared with normal); M, MET gene amplification (≥4-fold); NE, not evaluable because of lack of viable tumor cells.

  • *Two independent intrapulmonary metastatic lesions were analyzed and both harbored the same genetic alterations.

  • Three independent lymph nodes, 10R, 7, and 4L, were analyzed and all harbored the same genetic alterations.